The Indian Pharmacist Association (IPA) has submitted a detailed representation to Union Health Minister Jagat Prakash Nadda, urging the Government of India to comprehensively revise the Draft National Pharmacy Commission (NPC) Bill, 2026 before it is introduced in Parliament. The association has also separately requested the Ministry of Health & Family Welfare to issue nationwide implementation directions for the recently notified Pharmacist Recruitment, Promotion and Service Regulations.

The Central Government has officially amended the Drugs Rules, 1945, allowing Navi Mumbai Airport to be used as an authorized entry point for the import of drugs into India. The amendment has been notified through the Drugs (Ninth Amendment) Rules, 2026, which came into force upon its publication in the Official Gazette.

Marksans Pharma Ltd. has announced the acquisition of 100% share capital of ABCnow GmbH, a Germany-based pharmaceutical wholesale and distribution company, in a strategic move to strengthen its presence across regulated European markets. The company has entered into a definitive agreement to acquire the business as part of its forward integration strategy.

The acquisition will be completed through a cash consideration of €892,384, with the transaction expected to close by July 31, 2026. Marksans stated that no government or regulatory approvals are required for the acquisition.

The U.S. Food and Drug Administration (FDA) has approved Trutakna (atacicept-vymj) to reduce proteinuria (excess protein in the urine) in adults with primary Immunoglobulin A nephropathy (IgAN) who are at risk of disease progression. The approval provides a new treatment option for patients with this rare kidney disease, which can eventually lead to kidney failure.

CSIR-Indian Institute of Chemical Technology, Hyderabad (CSIR-IICT) is a Premier Research Laboratory under the Council of  Scientific & Industrial Research (CSIR), which is an autonomous body under the Ministry of  Science & Technology, Government of India.

Today Naprod Life Sciences is a dominant player in the Oncology and Anesthesia space not only in India but also globally. Naprod’s vision is to become a world-class player in Oncology through excellence in innovation, the discovery of new manufacturing processes/drug delivery mechanisms and a consistently high quality of production. Technical excellence & enthusiasm of our director Mr. Mohan B. Jain has been crucial in carrying forward the vision.

Hiring | Naprod Life Sciences Pvt. Ltd. Join growing team at our EU GMP-approved Injectable Plant, Boisar.